

CORRECTION

Open Access



Correction: Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes

Monica Gamez^{1*}, Hesham E. Elhegny¹, Sarah Fawaz¹, Kwan Ho Ho², Neill W. Campbell², David A. Copland³, Karen L. Onions¹, Matthew J. Butler¹, Elizabeth J. Wasson¹, Michael Crompton¹, Raina D. Ramnath¹, Yan Qiu¹, Yu Yamaguchi⁴, Kenton P. Arkill⁵, David O. Bates⁵, Jeremy E. Turnbull⁶, Olga V. Zubkova⁷, Gavin I. Welsh¹, Denize Atan^{3,8}, Simon C. Satchell¹ and Rebecca R. Foster¹

Following publication of the original article [1], the author noticed the error in Discussion section.

In the last paragraph under Discussion section, the sentence “The heterogenous nature of oligo-/polysaccharide derivatives such as PG545 also results in batch variations, further complicating FDA approval” is incorrect. In this text, PG545 should be replaced with SST0001 and should read “The heterogenous nature of oligo-/polysaccharide

derivatives such as SST0001 also results in batch variations, further complicating FDA approval”.

Published online: 20 February 2024

References

1. Gamez M, Elhegny HE, Fawaz S et al. Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes. *Cardiovasc Diabetol.* 2024;23:50. <https://doi.org/10.1186/s12933-024-02133-1>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1186/s12933-024-02133-1>.

*Correspondence:

Monica Gamez

mg14606@bristol.ac.uk

¹Bristol Renal, Bristol Medical School, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK

²Department of Computer Science, Merchant Venturers Building, University of Bristol, Woodland Road, Bristol BS8 1UB, UK

³Academic Unit of Ophthalmology, Translational Health Sciences, Bristol Medical School, University of Bristol, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, UK

⁴Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, CALa Jolla 92037, USA

⁵School of Medicine, Biodescovery Institute, University of Nottingham, Nottingham NG7 2UH, UK

⁶Centre for Glycoscience, School of Life Sciences, Keele University, Staffordshire ST5 5BG, UK

⁷Ferrier Research Institute, Victoria University of Wellington, 69 Gracefield Rd, Lower Hutt 5046, New Zealand

⁸Bristol Eye Hospital, University Hospitals Bristol & Weston NHS Foundation Trust, Bristol BS1 2LX, UK



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.